Posters

Intravitreal Bevacizumab for macular edema secondary to branch retinal vein oclusion

Poster Details

First Author: B.Kambo ALBANIA

Co Author(s):    A. Belshi              

Abstract Details

Purpose:

To evaluate the effect of intravitreal bevacizumab on the visual and anatomical outcome in eyes with macular edema secondary to branch retinal vein occlusion.

Setting:

Laser Eye Clinic Tirana , Albania

Methods:

A retrospective review was performed for 16 patients with a branch retinal vein occlusion treated with intravitreal bevacizumab. Clinical variables were analyzed, including best-corrected visual acuity, angiographic characteristics and central foveal thickness.

Results:

16 eyes were identified with a mean initial best-corrected visual acuity BCVA 0.14 and final best-corrected visual acuity 0.32 after the treatment .The mean initial central foveal thickness of 497 µm decreased to 259 µm . Mean number of injections was 2.5, and mean follow-up was 9 months.

Conclusions:

Intravitreal bevacizumab is an effective treatment for macular edema secondary to branch retinal vein occlusion in many subjects. Eyes treated with intravitreal bevacizumab showed a significant reduction in central foveal thickness and improvement in visual acuity. FINANCIAL DISCLOUSRE: NONE